LINK to Plenary Session

PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).

Abstract: LBA2: Deborah Schrag, Qian Shi, Martin Weiser, et al

Presenter: Deborah Schrag MD, FASCO, MPH

Zusammenfassung folgt

--------------------------------------------------------------------------------------------------------------------------

Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).

Abstract: LBA3: Roy Herbst, Masahiro Tsuboi, Tom John, et al.

Presenter: Roy S. Herbst, MD, PhD

Zusammenfassung folgt

--------------------------------------------------------------------------------------------------------------------------

SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).

Abstract: LBA4: Alex Herrera, Michael LeBlanc, Sharon Castellino, et al.

Presenter: Alex Francisco Herrera MD

Zusammenfassung folgt

Differential burnout by race, sex, and sexual orientation in academic oncology.

Abstract: 11000:

Presenter: Bismarck Odei

Zusammenfassung folgt

The ticking “biological clock”: Reproductive assistance, costs, and elective fertility preservation in female oncologists and trainees.

Abstract: 11001:

Presenter: Emily MacDuffie MD

Zusammenfassung folgt

Diversity, equity, & inclusion (DEI) and health equity (HE) education in hematology/oncology (HO) fellowship: A longitudinal curriculum.

Abstract: 11002:

Presenter: Norin Ansari MD, MPH

Zusammenfassung folgt